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Summary Two 9-dihydrotaxane analogues were synthesised and tested for in vitro potency and in vivo efficacy
against murine and human tumour xenografts in mice. The in vitro potency of 9-dihydrotaxol (9-DH-t) and 10-
deacetyl-9-dihydrotaxol (10-DeAc-9-DH-t) was generally less than that of paclitaxel against human and murine
tumour cells. However, both analogues were at least 20-fold more soluble than paclitaxel in water. The
analogues yielded cure rates > 60% against human MX-1 solid tumour xenografts in mice, compared with a
cure rate of 10% for mice treated with paclitaxel. Both of the analogues were more effective than paclitaxel for
treatment of murine M109 solid tumour in mice. 1O-DeAc-9-DH-t was as effective as paclitaxel against murine
B16 ascites tumour, while 9-DH-t was less effective. Both 10-DeAc-9-DH-t and 9-DH-t were demonstrably less
toxic than paclitaxel. At equal dosages 9-DH-t produced serum concentrations greater than paclitaxel, while
10-DeAc-9-DH-t yielded serum concentrations less than paclitaxel. However, the decrease in toxicity of 9-DH-t
and 10-DeAc-9-DH-t allowed a 4-fold increase in daily dosage. These two 9-dihydrotaxane analogues yielded
favourable preclinical data and demonstrated good potential for further development.
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As a new anti-cancer drug, paclitaxel has promising efficacy
but considerable clinical limitations owing to issues of supply,
solubility and toxicity. Paclitaxel is obtained from the bark of
the Pacific yew, Taxus brevifolia, and has demonstrated
potent in vitro cytotoxicity against murine and human cells
(Wani et al., 1971; NCI, 1990). The mechanism of action
involves stabilisation of microtubles with inhibition of
depolymerisation to free tubulin (Fuchs and Johnson, 1978;
Schiff et al., 1979; Schiff, 1980). This unique mechanism
stimulated development of paclitaxel despite initial limitations
in the supply of Taxus brevifolia. A commercially viable
synthetic route for paclitaxel is lacking, although a
semisynthetic route has helped ease the supply shortage.
Toxicity is the major factor limiting paclitaxel dosage and
potentially successful therapy. Paclitaxel also suffers from
limited solubility, necessitating the use of a cremophor
vehicle, which itself may induce toxicity. The development
of docetaxel demonstrated that analogues of paclitaxel can
have clinical potential (Bissery et al., 1991).
A novel taxane congener was recently isolated from an
extract of the Canadian bush Taxus canadensis (Gunawar-
dana, 1992). The novel structure of this compound and the
relatively good supply of Taxus canadensis allowed for the
preparation of 9-dihydrotaxol (Klein, 1993) and ring B-
rearranged taxane analogues (Klein et al., 1994). The fallen
needles and twigs of Taxus canadensis can be used in
preparation of starting material, eliminating the need to
harvest the entire bush. The 9-dihydrotaxane analogues retain
in vitro cytotoxicity comparable with paclitaxel and the
mechanism of action appears to be identical to that of
paclitaxel (Klein et al., 1994).
Two taxane analogues prepared from Taxus canadensis
starting material were tested for in vivo efficacy against
murine and human tumours. Efficacy was determined against
both ascites and solid tumours, including human tumour
xenografts. In vitro cytotoxicity, solubility and pharmacoki-
netic data were also determined for the analogues. The two
paclitaxel analogues presented in this report demonstrate
promising toxicity and efficacy data relative to paclitaxel. The
results support further development of these paclitaxel
analogues.
Methods
Synthesis of taxane analogues
The synthesis of the taxane analogues (Figure 1) has been
described in detail previously (Klein et al., 1994; Li et al.,
1994). Paclitaxel was obtained from NaPro Biotherapeutics,
Boulder, CO, USA.
In vitro evaluation of anti-tumour compounds
The in vitro potency of experimental and control taxanes was
determined using a colorimetric assay to assess cell
cytotoxicity as described previously (Chu et al., 1992).
Briefly, tumour cell lines were maintained in RPMI-1640
plus 10% fetal calf serum. Experimental and control taxane
compounds were dissolved in ethanol and added to the
tumour cells in 96-well microtitre plates. The cells were
exposed to compounds for 72 h. Cell viability was determined
by MTT dye reduction using absorbency at 470 nm. The
inhibitory concentration 50% (IC50) was determined as the
drug concentration to produce 50% cell cytotoxicty.
Animals
The mice used in the tumour tests were obtained from Harlan
Sprague-Dawley, Indianapolis, IN, USA. Female C57BL/
6 x DBA/2F1 (B6D2Fl/Hsd black, hereafter referred to as
BDFI) mice were housed ten animals to a cage on bedding
and given free access to food and water. Hsd:Athymic Nude-
nu (hereafter referred to as nude) mice were housed ten to a
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Figure 1 Structures of the paclitaxel analogues 9-DH-t and 10-
DeAc-9-DH-t. A-85576, 9-DH-t; Rl=Ac; A-86415, 10-DeAc-9-
DH-t; R1=H.
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cage in sterilised barrier cages and were given free access to
sterilised food and water. Outbred CD-1 mice used in
pharmacokinetic trials were obtained from Charles Rivers
Labs (Wilmington, MA, USA).
Tumour cells
P388, B16F1O, M109, HT29, A549, and MX-1 tumour cells
were obtained from American Type Culture Collection,
Rockville, MD, USA.
In vivo evaluations of anti-tumour compounds
B16 melanoma solid tumours were harvested from donor
mice and homogenised in a 1:20 weight to volume ratio using
a tissue homogeniser. (Tekmar, Cincinnati, OH, USA). The
resulting brei was injected intraperitoneally (i.p.) into BDF1
mice at 0.5 ml per mouse. This inoculation produced a
tumour ascites that was lethal in approximately 20 days in
untreated mice. Drug efficacy against i.p. tumour ascites was
evaluated by the per cent increase in life span (% ILS) based
upon mean survival time (MST) of treated vs untreated mice,
and on cures evaluated on 60 day survival rates. There were
ten mice in each dosage group and 20 untreated control mice
in each trial.
For M109 lung tumour trials breis were produced by
homogenisation of the solid M109 tumour tissue from the
flanks of donor mice. A 1:20 weight to volume brei was
prepared in sterile Hanks' balanced salt solution and 0.5 ml
was injected subcutaneously (s.c.) into the flanks of BDF1
mice. The solid tumour mass grew to a 1.0 g mass in 10- 12
days, and doubled in volume approximately every 2 days in
untreated mice. Drug efficacy against M109 subcutaneous
tumour inoculations was based upon delay in tumour growth
to 1.0 g (delay to 1.0 g), and upon tumour weight inhibition
(TWI) of treated tumour mass when control mean tumour
mass was approximately 1.0 g. Tumour mass was calculated
as (L x W2)/2. There were ten mice in each dosage group and
20 untreated control mice in each trial.
For xenograft solid tumour models, MX- 1 human
mammary inoculas were prepared by aseptic homogenisation
of solid tumour tissue. A 1:8 weight to volume brei was made
with MX-1 tumour tissue and 0.5 ml was injected s.c. into
nude mice. The solid tumour mass grew to a 0.5 g mass in
20-30 days and doubled in volume approximately every 7
days in untreated mice. Drug efficacy against s.c. MX-1
xenograft tumour inoculations was based upon delay in
tumour growth to 0.5 g (delay to 0.5 g), and TWI in treated
mice. The TWI was calculated when mean tumour mass of
untreated mice was approximately 0.5 g. There were ten mice
in each dosage group and 20 untreated control mice in each
trial. Mice were dosed on a Q.D. x 5 schedule based on the
MTD data obtained in earlier B16F1O trials.
Dosing
The taxanes were dissolved in 100% ethanol, which was then
diluted with cremophor to yield a 50:50 mixture. The
solutions were diluted with sterile injectable water (Abbott
Labs, North Chicago, IL, USA) to yield appropriate
concentrations, and were administered in a volume of
0.5 ml i.p. The final volumes of ethanol and cremophor
(Sigma, St Louis, MO, USA) combined were no more than
12% (6% each). The initial dose was administered 1 day after
tumour inoculation. Against B16FIO and MX-1 tumours the
taxane analogues were administered once daily for 5
consecutive days (days 1 -5 after inoculation). Against
M109 subcutaneous tumours the taxane analogues were
administered once daily, every fourth day for a total of
three injections (days 1, 5, 9 after inoculation). The schedules
for drug administration were adapted from general National
Cancer Institute guidelines for preclinical testing of anti-
tumour agents (NCI, 1985; Gerari et al, 1972). Dosages that
caused greater than 20% premature mortality (,<75% MST
of untreated mice) were classified as toxic. The maximum
tolerated dose (MTD) was determined as the highest drug
dose administered once daily for 5 consecutive days that
produced less than 20% mortality. The trials were performed
once.
Pharmacokinetics
Pharmacokinetic evaluation was performed on selected
compounds in male CD-1 mice (Charles Rivers Labs). The
mice were injected i.p. with the taxane compounds at
20 mg kg-'. The taxane compounds were formulated as
described above, with a final ethanol-cremophor-water
concentrations of 6%:6%:88%. At 0.25, 0.5, 1, 2, 4, 8 and
12 h after dosing groups of three mice were exsanguinated by
cardiac puncture and blood was collected into heparinised
tubes. Plasma was separated from cellular components by
centrifugation and was frozen at -70°C until analysis.
The compounds of interest were separated from plasma
contaminants by utilising a liquid-liquid extraction with a
mixture of ethylacetate and hexane. The samples were
evaporated to dryness, reconstituted and then chromato-
graphed on a 5 cm x 4.0 mm 3 gM YMC-C8 column with an
acetonitrile-methanol-trifluoroacetic acid (0.1%) in 0.01 M
tetramethylammonium perchlorate mobile phase at a flow
rate of 1.0 ml min-' with low-wavelength u.v. detection of
the analytes at 205 nm. The analytical methods for parent
drug were linear (correlation coefficient >0.99) over the
concentration range 0-22 pg ml-1 with a mean per cent
standard deviation<3% for the analysis of triplicate mouse
plasma standards at six different concentrations. The limit of
quantitation from a 0.3 ml plasma sample was estimated to
be 0.1 jug ml-' based on recovery of parent drug from spiked
samples. Plasma samples with concentrations of drug in
excess of the linear range of the standard curve were diluted
and reassayed to provide a value within the linear
concentration range. The peak plasma concentration (Cmax)
and time to peak plasma concentration (Tmax) were derived
from the three highest calculated plasma concentrations. The
area under the curve (AUC) values were calculated by the
trapezoidal method over the time course of the study (0-
12 h) using the mean plasma concentration of parent drug at
each time point.
Statistical analysis
Delay in solid tumour growth for treated and untreated mice
was compared using the Student-Neuman-Keuls test
following an ANOVA of the tumour growth that rejected
the null hypothesis. The chi-square test was used for analysis
of per cent cures of treated vs untreated mice in the MX-1
trial. A significance level of 0.05 was used for comparisons in
the solid tumour trials. In the B16 ascites tumour trial means
of survival time were compared using the Student t-test for
unpaired data with a significance level of 0.05.
Results
In vitro cell cytotoxicity
The paclitaxel analogues A-85576, 9-dihydrotaxol (9-DH-t),
and A-86415, 10-deacetyl-9-dihydrotaxol (10-DeAc-9-DH-t),
produced IC50 values that ranged from equally to 8-fold less
potent than paclitaxel (Table I). 10-DeAc-9-DH-t was as
Table I In vitro tumour cell cytotoxicity of taxane analogues
IC50 (ngml- )a Solubility b
Compound A549 HT-29 BJ6FJO P388 (pgml ')
A-85576 (9-DH-t) 19.0 8.0 25 53.0 226
A-86415 (10-DeAc-9-DH-t) 11.0 1.9 39 14.0 69
Paclitaxel 3.4 2.7 4.9 9.9 2.92
ane ml- to produce 50% cytotoxicity in the indicated tumour cell
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potent as paclitaxel against HT29 and P388 tumour cells, but
was 3- to 8-fold less potent vs A549 and B16F10 cells
respectively. 9-DH-t was 3- to 5-fold less potent than
paclitaxel against the four tumour cell lines. The water
solubility of 9-DH-t was approximately 75-fold greater than
paclitaxel. The water solubility of 10-DeAc-9-DH-t was
approximately 20-fold that of paclitaxel.
In vivo MTD doses in mice
When administered i.p. once daily for 5 consecutive days, the
maximum tolerated dose (MTD) of paclitaxel was
25 mg kg-' day-', while the MTDs of 9-DH-t and 10-
DeAc-9-DH-t were greater than 100 mg kg-' day-'. The
MTDs were determined in BDF mice bearing B16FlO ascites
tumours (Table II).
Table II In vivo lethal dose 50% (LD50) and maximum tolerated
dose (MTD) values (mg kg 'per day) for taxane analogues in mice
following single and multiple doses by i.p. route
MTDa
Compound (q.d. days 1-5)
A-85576 (9-DH-t) > 100
A-86415 (I0-DeAc-9-DH-t) > 100
Paclitaxel 25
aMaximum dose (mg kg-'per day) that yielded <20% lethality
following five i.p. doses, administered once daily in BDF mice bearing
B16F1O ascites tumours.
Efficacy of taxane analogues vs i.p. B16F10 murine melanoma
At non-toxic doses the paclitaxel analogues 9-DH-t and 10-
DeAc-9-DH-t optimally produced 39% and 83% increase in
life span (ILS) and cure rates of 0% and 10% respectively
(Table III). Paclitaxel treatment produced a 96% ILS and a
0% cure rate. Untreated mice survived approximately 20
days. The optimal dosage for paclitaxel was 25 mg kg-'
day-' when administered i.p. once daily for 5 consecutive
days. On the same schedule the optimal doses of the
paclitaxel analogues 9-DH-t and 10-DeAc-9-DH-t were 50
and 100 mg kg-' day-'. There was a dose-response effect to
paclitaxel and the analogues.
Efficacy of taxane analogues vs subcutaneous M109 murine
solid tumour
The paclitaxel analogues 9-DH-t and 10-DeAc-9-DH-t
yielded 10.5 and 5.1 day delays in solid tumour growth to
1 g (Table IV). Paclitaxel at a non-toxic dose produced only
a 0.6 day delay in tumour growth to 1 g. Untreated mice
yielded tumours with a mass of 1 g in 12 days. There was a
0% cure rate for all compounds. The tumour weight
inhibition. (TWI) when untreated mice had a mean tumour
mass of 1 g was 79-90% for the taxane analogues,
compared with 47% for mice treated with paclitaxel. When
administered i.p on a schedule of every fourth day for three
total injections (days 1, 5, 9 after inoculation), the optimal
doses of 9-DH-t and 10-DeAc-9-DH-t were 100 mg kg-'
injection. There was a general dose reponse to all three
compounds.
Table III In vivo efficacy of 9-dihydrotaxol and 10-deacetyl-9-dihydrotaxol vs murine B16F10 melanoma ascites tumour
Compound Dosea MSTb %ILY Per cent toxicityd Per cent curese
A-85576 (9-DT-t) 100 28.7± 12.6f 46 20 0
50 27.3 i4.9' 39 0 0
25 23.9+4.3 21 0 0
A-86415 (10-DeAc-9-DH-t) 100 34.8 ±4.5f 77 0 0
50 36.1 +4.5f 83 0 10
25 30.0+11.Of 52 0 0
Paclitaxel 25 38.6 +4.8f 96 0 0
12.5 26.4±3.4f 34 0 0
6.25 26.4+ 3.4f 34 0
Untreated NA 19.7+2.7 NA NA NA
amg kg-'per day, q.d., i.p., days 1 -5 after inoculation. bMean survival time (days) + s.d. cGroup mean increase in lifespan. dPercentage ofmice
with premature death. ePercentage ofmice alive 60days afterinoculation. rSignificantly different from untreated mice (P<0.05). NA, notapplicable.
Table IV In vivo eflicacy of taxane analogues vs murine M109 solid tumour
Compound Dosea TWt Days (JI g)C Delay (1.0g)d Per cent toxicity Per cent curese
A-85576 (9-DH-t) 100 90 22.s57.7f 10.5 0 0
50 46 14.1+3.2 2.1 0 0
25 34 13.6+2.3 1.6 0 0
A-86415 (10-DeAc-9-DH-t) 100 79 17.1 ±2.6' 5.1 0 0
50 19 12.0+0 0 0 0
25 10 12.0+0 0 0 0
Paclitaxel 25 47 12.9± 1.1 0.9 30 0
12.5 40 12.6+ 1.0 0.6 0 0
6.25 22 12.4±0.8 0.4 0 0
Untreated NA NA 12.0+0 NA NA NA
amgkg 'per day, q.d., i.p., days 1, 5, 9 after inoculation. bPer cent tumourweight inhibition when untreated control mean = 1.0g.cDays to reach
mean tumour mass = 1.0g ±s.d. dDelay (days) to reach mean tumour mass = 1.0g, compared with untreated. ePercentage ofmice with no palpable
tumours, day 60. fSignificantly different from untreated mice (P<0.05). NA, not applicable.
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Efficacy of taxane analogues vs human MX-J mammary solid
tumour xenograft
The taxane analogues 9-DH-t and 10-DeAc-9-DH-t produced
21 and 33 day delays in tumour growth compared with
untreated controls (Table V). When administered once daily
on days 1-5 after inoculation there was a 60% and 70%
cure rate for 9-DH-t and 10-DeAc-9-DH-t. The optimal dose
for these two compounds was 100 mg kg-' per dose on this
schedule. Paclitaxel yielded a 13.4 day delay in MX-1 tumour
growth and a 10% cure rate compared with untreated
animals. The optimal dosage for paclitaxel was 12.5 mg kg-'
per dose when administered on days 1-5 after inoculation vs
MX-1 tumour in nude mice.
The two analogues optimally produced a tumour weight
inhibition of 98-100% against MX-1 when untreated mice
had a mean tumour mass of 0.5 g. Paclitaxel yielded a TWI
value of 80% at non-toxic doses.
Pharmacokinetic properties of taxane analogues following i.p.
dosing in mice
9-DH-t yielded Cmax values of 40 jg ml-' plasma at 0.5 h
after dosing (Table VI). The AUC value of over
75 pgh-' ml-' for 9-DH-t was the largest value observed
for the three compounds. 10-DeAc-9-DH-t produced a Cmax
of 11 jIg ml-' at 1.5 h after administration. The AUC value
for 10-DeAc-9-DH-t was 30 jig h-' ml-'. Paclitaxel yielded a
Cmax of 14 jig ml-' at 1.5 h after administration and an AUC
value of 43 jg h-' ml-'. The t1/2 values for 9-DH-t, 10-
DeAc-9-DH-t and paclitaxel were 1.9, 2.8, 2.9 h.
Discussion
The two taxane analogues showed favourable solubility,
toxicity and efficacy profiles relative to paclitaxel. Both 10-
DeAc-9-DH-t and 9-DH-t demonstrated less toxicity than
paclitaxel, and considerable efficacy vs murine and human
solid tumours in vivo. A decrease in lethal toxicity allowed
higher daily doses to be administered for the analogues. The
in vitro potency of the taxane analogues was within one log
of that of paclitaxel, but there was no clear correlation
between in vitro potency and in vivo efficacy.
The mouse models of tumour growth are valid indicators
of potential clinical utility of paclitaxel analogues. Both
ascites and solid tumour mouse models are commonly used
as screens for preclinical efficacy (Gerari et al., 1972). Efficacy
vs solid tumours has gained prominence as a means oftesting
for an unmet clinical need, compared with efficacy vs ascites
tumours. For paclitaxel analogues efficacy in human solid
tumour xenograft models is considered an indicator for
preclinical efficacy. Paclitaxel efficacy vs murine tumour lines
tended to be less than that vs human tumours. While effective
therapy against murine or human xenografted tumours does
not ensure clinical success, efficacy in these models gives
credibility to the clinical potential of taxane analogues.
Both of the analogues demonstrated efficacy that
compared favourably with paclitaxel vs murine M109 and
human MX-1 solid tumour xenograft. The efficacy of
paclitaxel vs M109 in these trials was less than that reported
previously (Rose, 1981, 1991). However, different routes of
administration and formulations of paclitaxel were used in
the other studies. These studies tested the taxane analogues in
equal formats for purposes of an initial in vivo comparison.
Efficacy vs solid tumours is an important preclinical marker
for potential clinical efficacy of anti-tumour drugs.
The efficacy of the taxane analogues vs ascites B16 tumour
provided additional evidence for activity of the analogues,
since paclitaxel is more reliably effective against i.p. tumours
than against s.c. tumours (Rose, 1981; Lavelle et al., 1989).
There was no clear correlation between in vitro potency and
in vivo efficacy vs B16 ascites tumour. Against B16 ascites 10-
DeAc-9-DH-t was equal to or better than paclitaxel, while 9-
DH-t was less effective.
The i.p. pharmacokinetic studies in mice were used as a
basic test of bioavailability in the tumour test system, rather
than as an exhaustive pharmacokinetic analysis. The efficacy
of paclitaxel therapy is dependent upon the route of
administration; with i.p. dosing paclitaxel therapy is usually
effective against ascites tumours (Rose, 1981). The high Cmax
and AUC values attained following i.p. dosing suggest good
Table V In vivo efficacy of taxane analogues vs human MX-1 xenograft solid tumour
Compound Dosea TWJb Days to J.ogc Delay (1.0g)d Per cent toxicity Per cent curese
A-85576 (9-DH-t) 100 98 49.0±17.Of 21.1 0 60f
50 94 40.3 ±3.5f 12.4 0 f
25 65 33.8 ± 5.5 5.9 0 0
12.5 31 29.5 ±7.6 1.6 0 0
A-86415 (10-DeAc-9-DH-t) 100 100 61.0 ±of 33.1 0 70f
50 99 42.6 ±7.7' 14.7 0 30
25 73 33.3 +7.6 5.4 0 10
12.5 27 28.0± 5.7 0 0 20
Paclitaxel 25 100 47.0+Of 19.1 40 30
12.5 80 41.3± 9.7f 13.4 0 10
6.25 42 29.3 ± 5.0 1.4 0 0
Untreated NA NA 27.9 ± 5.0 NA NA NA
amgkg- 1 per day, q.d., i.p., dadys 1 -5 after inoculation. bPercent tumour weight inhibition when untreated control mean= 0.5g. cDays to reach
mean tumour mass =0.5g± s.d. Delay (days to reach mean tumour mass =0.5g, compared with untreated. ePercentage ofmice with no palpable
tumours, day 60. fSignificantly different from untreated mice (P<0.05). NA, not applicable.
Table VI Pharmacokinetic properties of 9-dihydrotaxane analogues in mice
Compound' Cmax (igml ') Tmax (h) t. (h) AUC (,ig per h ml-')
A-85576 (9-DH-t) 40.32 0.58 1.9 75.62
A-86415 (10-DeAc-9-DH-t) 11.19 1.40 2.8 29.81
Paclitaxel 14.13 1.50 2.9 42.53
aCompounds dosed at 20 mgkg- ' i.p.Oe^- Efficacy of 9-dihydrotaxane analogues
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bioavailability for both analogues. The serum levels and
AUC values of 9-DH-t were greater than paclitaxel, while the
serum levels of 10-DeAc-9-DH-t was less than paclitaxel at
equal dosages. The t,/2 values for 9-DH-t and paclitaxel were
similar (2.8 and 2.9 h), suggesting a potential dosing
advantage for the analogue based on the decrease in
toxicity. Pharmacokinetic studies in mice must be interpreted
with caution owing to the higher variability between animals.
The decrease in apparent toxicity of the analgoues relative
to paclitaxel was encouraging. The analogues were tolerated
at daily i.p. doses of 100 mg kg-' day-', which was 4-fold
greater than paclitaxel. This decrease in toxicity allowed the
analogues to be administered at higher doses, resulting in
greater efficacy. Some reports suggest that daily doses of
paclitaxel may be superior to larger, less frequent doses (NCI,
1985). Both 9-DH-t and 10-DeAc-9-DH-t were better
tolerated than paclitaxel. In general, nude mice did not
tolerate daily doses of the taxane analogues as well as other
mice and paclitaxel showed variability in maximum tolerated
dose between trials. In the M109 and MX-1 solid tumour
trials paclitaxel at 25 mg kg-' was not tolerated (30% and
40% mortality), while daily doses of 25 mg kg-' were
tolerated in the B16 ascites tumour trials. The optimal
balance of efficacy and toxicity has not been yet been
determined with taxane analogues.
The efficacy of the taxane analogues relative to paclitaxel
suggests potential clinical utility. Paclitaxel has demonstrated
clinical efficacy vs human breast and ovarian tumours
(McGuire et al., 1989; Thigpen et al., 1990). Reponse rates
of 48% were recorded in breast tumour patients who had
failed one previous course of chemotherapy (Holmes et al.,
1991). Paclitaxel has been used against other tumours,
including leukaemia and malignant melanoma (Einzig, 1988;
Rowinsky et al., 1989). A 30% response rate against ovarian
tumours that had failed cisplatinum therapy was obtained
with paclitaxel (McGuire et al., 1989). The clinical use and
efficacy of docetaxel has generated additional support for this
base structure (Chabner et al., 1991; Ringel and Horwitz,
1993). The preclinical efficacy and toxicity profiles of the
taxane analogues in relation to paclitaxel may be extended to
project potential clinical use.
In summary, two taxane analogues were tested for efficacy
in mouse models of solid and ascites tumours. These
analogues were generally superior or similar to paclitaxel in
efficacy. The analogues 9-DH-t and 10-DeAc-9-DH-t yielded
less toxicity and greater water solubility than paclitaxel. The
preclinical efficacy of these two compounds supports further
development.
Abbreviations
9-DH-t, 9-dihydrotaxol; 10-DeAc-9-DH-t, 10-deacetyl-9-dihydro-
taxol; IC50, 50% inhibitory concentration; %ILS, per cent increase
in lifespan; TWI, tumour weight inhibition; Cmax, maximum serum
concentration; Tmax, time to maximum concentration; AUC, area
under the curve; LD50, 50% lethal dose; MTD, maximum tolerated
dose.
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